hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
Shore Capital Reaffirms Buy Rating on hVIVO Despite Share Price Weakness
Shore Capital has maintained its Buy rating on hVIVO PLC, the specialist contract research organisation, with a fair value assessment of 25 pence per share.
Emerging Small Cap Investment Opportunities
Small-cap stocks represent some of the more appealing opportunities for investors who enjoy diversifying their portfolios and capitalizing on high growth potential. The typical small-cap company, within the valuation bracket
Destiny Pharma PLC (AIM:DEST) Last Day of Dealings on AIM
Brighton, United Kingdom – 12 August 2024 – Destiny Pharma plc (AIM: DEST), a clinical-stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life-threatening
Sareum Holdings PLC (AIM:SAR) Update on SDC-1801 Clinical Trial Progress
Cambridge, UK, 15 February 2024 – Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the completion of the single ascending
Tiziana’s lead candidate shows positive safety profile and clinical response
Tiziana Life Science Ltd is a biopharmaceutical firm in the clinical stage that develops breakthrough therapies by utilizing transformational drug-delivery technologies.
Redx Pharma is advancing with ts primary asset, RXC007
Redx Pharma PLC (AIM: REDX) announced that its primary asset, RXC007, is successfully moving through phase IIa testing, with anticipated results from the idiopathic pulmonary fibrosis research due in the
Cellular Goods PLC – Products to launch on Sephora.co.uk
Cellular Goods (LSE: CBX), a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, is pleased to announce that it has entered into a contract with
OKYO Pharma is scheduled to present data on their dry eye drug at an important conference.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US
Activation of First Clinical Trial Site in the U.S
OKYO Pharma LTD has commenced the trial process for its treatment of dry eye disease.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Limited (AIM:OKYO) Custom Clearance of GMP Packaged OK-101 Drug
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease